Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation
Recruiting
Observational Study
Severe COVID-19
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 74
- Sex
- Any
- Study type
- Observational
- Participants needed
- 72 (estimated)
- Sponsor
- Assistance Publique - Hôpitaux de Paris · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
ICU Patients admitted after ARDS due to COVID infection should be weaned from invasive mechanical ventilation as quickly as possible.
60% of ARDS patient after COVID infection admitted in ICU developp a delirium during mechanical ventilation weaning, serious event that can lead to death or acute and late complications since 30% of patients who had a delirium in ICU develop cognitive sequelae. Bas…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adult patient (age ≥ 18 years at the time of inclusion) under 75 years old
* COVID-19 infection documented by PCR test performed on a nasopharyngeal swab or from a bronchoalveolar sample
* High affinity homozygous TPSO genotyping for \[18F\] -DPA-714 or heterozygous intermedia…
Contacts